stars 1 stars 2 stars 3

RefLab is a Danish biotech company located in Copenhagen founded in 1991 as a spin-off of Lundbeck and now a member of R-Biopharm group in Germany. RefLab has proven track record with several big pharma companies together with established scientific collaborations with national and international universities and hospitals. We offer clinical sample testing for chronic spontanous urticaria and preclinical contract research within PK/PD, translational studies assessing potential hypersensitivity and toxicological effects as well as drug metabolism studies in a human ex vivo immune model. RefLab has a pre-existing ethical clearance, no time delays for project start-up. Applications for RefLab human ex vivo skin-based immune model is: Pharmacokinetics and pharmacodynamics Translational studies – from animal to man Hypersensitivity reactions to pre-clinical drugs Drug metabolism in human skin Cytokine profiling and inflammatory responses Protein detection and assessment of biological activity RefLab also has an accredited Service Laboratory with extensive expertise in drug allergy and chronic urticaria testing, serving hospitals, clinics, allergy, immunology & dermatology specialists. Please also find us on Scientist.com: https://app.scientist.com/domain_switcher?redirect=/providers/reflab-aps

RefLab ApS Questions

The RefLab ApS annual revenue was $5 million in 2026.

Maja Michelsen is the CFO of RefLab ApS.

10 people are employed at RefLab ApS.

RefLab ApS is based in København N, Capital Region.

The NAICS codes for RefLab ApS are [54, 541714, 5417, 54171, 541].

The SIC codes for RefLab ApS are [87, 873].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users